Holcim: The Group shows organic growth at operating EBITDA level. Important key figures of the Group have improved in comparison with the first half of 2009, and the company has achieved further growth. The Group benefited from its strong presence in the emerging markets, which accounted for more than 50 percent of consolidated net sales and more than 70 percent of operating EBITDA in the first half of the year. Link: Click Here

Schlatter Group results for the first half of 2010. Order intake improves but remains at a low level. Sales slightly below same period of 2009. Positive operating result of CHF 1.9 million. Despite positive signs, the Schlatter Group once again felt the effects of the economic crisis in the first half of 2010 in the form of continued very low market volumes. The order intake rose by 99.3 percent to CHF 60.8 million compared to the first half of 2009 (CHF 30.5 million) but remained significantly below earlier levels. Link: Click Here

Schweiter: Orders received reached CHF 536.6 million in the first half.  Gross revenues amounted to CHF 481.5 million.  The significant increase in volume is attributable to the acquisition of 3A Composites, completed at the end of November 2009, and to the positive business performance in all divisions. Link: Click Here

Straumann: Amid continued sluggish market conditions, the Straumann Group today reported top-line growth of 4% (l.c.) over the first six months of 2010, bringing net revenues to CHF 392 million. Growth momentum increased to 5% (l.c.) in the second quarter, when the number of trading days was identical to the comparative prior-year period.  There were no material acquisition effects in 2010. The strength of the Swiss franc against the Euro and other currencies resulted in a negative currency effect of 2% points. As a result, net revenue growth amounted to 2% in Swiss francs. Link: Click Here

Basilea Pharmaceutica Ltd. (SIX:BSLN) significantly increases revenues and cash position in the first half of 2010. Basilea Pharmaceutica Ltd. announced today its 2010 interim financial results reflecting the positive impact of the partnering agreement with Astellas Pharma Inc. for Basilea's phase III antifungal agent isavuconazole; the continued commercial roll-out of Toctino® (alitretinoin) for the treatment of severe chronic hand eczema including a distribution agreement with Almirall, S.A.; and the positive one-time impact from the accelerated recognition of upfront and milestone payments related to the antibiotic ceftobiprole. Link: Click Here